Revolutionizing Drug Treatment with Microchip Biotechnology

Drug treatment/ prescriptions are becoming increasingly complex and hard to manage. With the introduction of microchip technology, there is a potential easier way for people with health issues to be given treatment. A one-time chip that releases medicine on a timer with a measured amount. More than 30 million people in the US don't have access to health insurance. Microchips could change that.
People Impacted
$ 1.7T
Potential Funding
I have this challenge
the problem
Nature and Context

As drug therapies become increasingly complex and effective in treating disease, the development of delivery systems has overcome challenges of achieving stable release rates, drug concentrations, and being at a specific site of action. Traditional routes of administration, such as oral capsules or intravenous infusion, encounter problems in maintaining drug concentrations within the therapeutic window, wherein the drug is above a threshold for efficacy but not toxic to the patient. Thus, the design of delivery systems initially focused on attaining a sustained release of drug over a time interval. Much of this work focused on polymers and their material properties that allow for steady-state diffusion of drug out of the polymer or degradation of the polymer itself over time. In addition to sustained release, pulsatile delivery at variable time intervals is necessary for compounds, such as insulin or hormones of the anterior pituitary, for physiological functions that follow either circadian rhythm or a time structure.

Ideas Description

Microchips Biotech creates microchip-based implants that are self-contained,  hermetically sealed drug delivery devices. They can be implanted and removed within a doctor's office and can store hundreds of doses that can last months, or even years. The device can be controlled by the patient or the doctor via a wireless remote and can be pre-programmed to release the drug at precise times. The core technology was originated out of labs at MIT and has been clinically validated in human studies delivering Parathyroid hormone (PTH) in osteoporosis patients. It has since been under development for applications in multiple therapeutic indications including osteoporosis, diabetes, multiple sclerosis and women’s contraception.

Input Needed From Contributing Editors
(click on any tag to contribute)